Maikel Peppelenbosch (b. 1967) studied medicine at the University of Utrecht, Utrecht, The Netherlands and trained in medical biology between 1985 and 1989. In 1994, Peppelenbosch completed his thesis (cum laude) on the "Action and function of receptor protein tyrosine kinases: The role of arachidonic acid metabolites and tyrosine phosphatases". He subsequently became a Postdoctoral Associate from 1993–1995 with Dr. Johannes L. Bos, Physiological Chemistry, Utrecht University and then with Dr. Anne Ridley, Ludwig Institute for Cancer Research, London and with Dr. Walter Fiers in Gent, Belgium. After return to The Netherlands, he became a Research Leader at the Laboratory for Experimental Internal Medicine, Academical Medical Center, Amsterdam. In July 2004 he became a Professor of cell biology and Chairman of the Immunology, Department of Cell Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. In December 2009 Peppelenbosch became a Professor of Experimental Gastroenterology and Head of the Laboratory of Gastroenterology and Hepatology at the Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands. In 2004 he initiated a trial employing IL-10 producing l. lactis for the treatment of Crohn's disease, which was the first trial ever in which humans were treated with a genetically modified organism and showed that mucosal delivery of biologicals using this route is possible.
Biography Updated on 8 December 2010